Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562

British Journal of Haematology

Volumn 106, Issue 1, 1999, Pages 78-85

  Dumontet, Charles ^g   Fabianowska Majewska, Krystyna ^a   Mantincic, Danko ^b   Callet Bauchu, Evelyne ^h   Tigaud, Isabelle ^h   Gandhi, Varsha ^c   Lepoivre, Michel ^d   Peters, Godefridus J ^e   Rolland, Marie Odile ^h   Wyczechowska, Dorota ^a   Fang, Xiao ^f   Gazzo, Sophie ^h   Voorn, Daphne A ^e   Vanier Viornery, Armelle ^h   Mackey, John ^f  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CNRS   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CROSS CANCER INSTITUTE   (Canada)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h NONE

Author keywords

Chemoresistance; Deoxycytidine kinase; Leukaemia; Nucleoside analogues; Nucleotidase

Indexed keywords

CLADRIBINE; CYTARABINE; FLUDARABINE; GEMCITABINE; NUCLEOSIDE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG DEGRADATION; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CLADRIBINE; CYTARABINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; PHENOTYPE; VIDARABINE;

EID: 0013040873     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01509.x     Document Type: Article

References (40)

1. Belt, J.A., Marina, N.M., Phelps, D.A. & Crawford, C.R. (1993) Nucleoside transport in normal and neoplastic cells. Advances in Enzyme Regulation, 33, 235-252.
2. Boletti, H., Coe, J.R., Baldwin, S.A. & Cass, C.E. (1997) Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology, 36, 1167-1179.
3. Burris III, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., Nelson, R., Dorr, A., Stephens, C.D. & Von Hoff, D.D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15, 2403-2413.
4. Callet-Bauchu, E., Rimokh, R., Tigaud, I., Pages, J., Gazzo, S., Bastion, Y., Sebban, C., Magaud, J.P. & Coiffier, B. (1996) dic(4:17) (p11:p11): a new recurrent chromosomal abnormality in chronic B-lymphoid disorders. Genes, Chromosomes and Cancer, 17, 185-190.
5. Cheson, B.D. (1992) New antimetabolites in the treatment of human malignancies. Seminars in Oncology, 19, 695-706.
6. Crawford, C.R., Patel, D.H., Naeve, C. & Belt, J.A. (1998) Cloning of the Human equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter by functional expression in a transport-deficient line. Journal of Biological Chemistry, 273, 5288-5293.
7. Dumontet, C., Duran, G.E., Steger, K.A., Murphy, G., Sussman, H. & Sikic, B.I. (1996) Differential expression of tubulin isotypes during the cell cycle. Cell Motility and the Cytoskeleton, 35, 49-58.
8. Flasshove, M., Strumberg, D., Ayscue, L., Mitchell, B.S., Tirier, C., Heit, W., Seeber, S. & Schutte, J. (1994) Structural analysis of the deoxycyticine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia, 8, 780-785.
9. Fox, M., Boyle, J.M. & Kinsella, A.R. (1991) Nucleoside salvage and resistance to antimetabolite anticancer agents. British Journal of Cancer, 64, 428-436.
10. Gandhi, V., Danhauser, L. & Plunkett, W. (1987) Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. Journal of Chromatography, 413, 293-299.
11. Gandhi, V., Estey, E., Keating, M.J. & Plunkett, W. (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia. Blood, 87, 156-164.
12. Gandhi, V., Huang, P., Chapman, A.J., Chen, F. & Plunkett, W. (1997) Incorporation of fludarabine and 1-β-D-arabinofuranosylcytosine 5′-triphosphates by DNA polymerase alpha: affinity, interaction and consequences. Clinical Cancer Research, 3, 1347-1355.
13. Griffig, J., Koob, R. & Blakley, R.L. (1989) Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Research, 49, 6923-6928.
14. Griffiths, M., Beaumont, N., Yao, S.Y.M., Sundaram, M., Boumah, C.E., Davies, A., Kwong, F.Y.P., Coc, I., Cass, C.E., Young, J.D. & Baldwin, S.A. (1997a) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nature Medicine, 3, 89-93.
15. Griffiths, M., Yao, S.Y.M., Abidi, F., Phillips, S.E.V., Cass, C.E., Young, J.D. & Baldwin, S.A. (1997b) Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochemical Journal, 328, 749-743.
16. Grunewald, R., Kantarjian, H., Du, M., Faucher, K., Tarasoff, P., Plunkett, W. (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. Journal of Clinical Oncology, 10, 406-413.
17. Hopkinson, D.A., Cook, P.J.I., & Harris, H. (1969) Further data on the adenosine deaminase polymorphism and report of a new phenotype. Annals of Human Genetics, 32, 361-365.
18. TSCN (1995) An International System for Human Cytogenetic Nomenclature. Karger, Basel.
19. Iwasaki, H., Huang, P., Keating, M.J. & Plunkett, W. (1997) Differential incorporation of Ara-C, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood, 90, 270-278.
20. Jeannesson, P., Trentesaux, C., Gerard, B., Jardillier, J.C., Ross, K.L. & Tokes, Z.A. (1990) Induction of erythroid differentiation in human leukemic K-562 cells by membrane-directed action of adriamycin covalently bound to microspheres. Cancer Research, 50, 1231-1236.
21. Juliusson, G. & Liliemark, J. (1996) Long-term survival following cladribine therapy in previously treated patients with chronic lymphocytic leukemia. Annals of Oncology, 7, 373-379.
22. Kawasaki, H., Carrera, C.J., Piro, L.D., Saven, A., Kipps, T.J. & Carson, D.A. (1993) Relationship of deoxycytidine kinase and cytoplasmid 5′ nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood, 81, 597-601.
23. Keating, M.J., O'Brien, S., Kantarjian, H., Plunkett, W., Estey, E., Koller, C., Beran, M, & Freireich, E.J. (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 11, 2878-2884.
24. Kroep, J.R., van Moorsel, C.J., Veerman, G., Voorn, D.A., Schultz, R.M., Worzalla, J.F., Tanzer, L.R., Merriman, R.L., Pinedo, H.M. & Peters, G.J. (1998) Role of deoxycytidine kinase, thymidine kinase 2, and deoxycytidine deaminase in the antitumour activity of gemcitabine. Advances in Experimental Medicine and Biology, 431, 657-660.
25. Lepoivre, M., Chenais, B., Yapo, A., Lemaire, G., Thelander, L. & Tenu, J.P. (1990) Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. Journal of Biological Chemistry, 265, 14143-14149.
26. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. (1951) Protein measurement with Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
27. Mackey, J.R., Baldwin, S.A., Young, J.D. & Cass, C.E. (1998) Nucleoside transport and its significance for anticancer drug resistance. Drug Resistance Updates, 1, 310-324.
28. Plunkett, W., Hug, V., Keating, M.J. & Chubb, S. (1980) Quantification of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Research, 40, 588-591.
29. Richel, D.J., Colly, L.P., Arkesteijn, G.J.A., Arentsen-Honders, M.W., Kerster, M.G.D., ter Riet, P.M. & Willemze, R. (1990) Substrate-specific deoxycytidine kinase deficiency in 1-β-D-arabinofuranosylcytosine-resistant leukemic cells. Cancer Research, 50, 6515-6519.
30. Rodriguez, C.O., Legha, J.K., Estey, E., Keating, M.J. & Gandhi, V. (1997) Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clinical Cancer Research, 3, 2107-2113.
31. Ruiz van Haperen, V.W., Veerman, G., Braakhuis, B.J., Vermoken, J.B., Boven, E., Leyva, A. & Peters, G.J. (1993) Deoxycytidine kinase and deoxycytidine deaminase activities in human tumor xenografts. European Journal of Cancer, 29A, 2132-2137.
32. Ruiz van Haperen, V.W.T., Veeman, G., Eriksson, S., Boven, E., Stegmann, A.P.A., Hermsen, M., Vermorken, J.B., Pinedo, H.M. & Peters, G.J. (1994) Development and characterization of a 2,2-difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Research, 54, 4138-4143.
33. Santoro, A., Devizzi, L., Bonfante, V., Viviani, S., Soto Parra, H., Nowrousian, M., Seeber, S., Hiddemann, W., Oliva, C., Pacini, M., Buksmaui, S., Bonadonna, G. & Diehl, V. (1997) Phase II study with gemcitabine in pretreated patients with Hodgkin's disease and non-Hodgkin's lymphoma: results of a multicenter study. American Society of Clinical Oncology, Abstract 71.
34. Sherman, P.A. & Fyfe, J.A. (1989) Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Analytical Biochemistry, 180, 222-226.
35. Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. & Cheson, B.D. (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute: five-year follow-up report. Journal of Clinical Oncology, 15, 458-465.
36. Stegmann, A.P.A., Honders, M.W., Kester, M.G.D., Landegent, J.E. & Willemze, R. (1993) Role of deoxycytidine kinase in an in vitro model for ara-C and DAC resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-arabinofuranosylcytosine and 5-aza-2-deoxycytidine. Leukemia, 7, 1005-1011.
37. Twentyman, P.R., Fox, N.E. & Rees, J.K. (1989) Chemosensitivity testing of fresh leukaemic cells using the MTT colourimetric assay. British Journal of Haematology, 71, 19-24.
38. Ujhazy, P., Berleth, E.S., Pietkiewicz, J.M., Kitano, H., Skaar, J.R., Ehrke, M.J. & Mihich, E. (1996) Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. International Journal of Cancer, 68, 493-500.
39. Van Laarhoven, J.P.R.M., Spierenburg, G.T. & De Bruyn, C.H.M.M. (1980) Enzymes of purine nucleotide metabolism in human lymphocytes. Journal of Immunological Methods, 39, 47-58.
40. Warzocha, K., Fabianowska-Majewska, K., Blonski, J., Krykowski, E. & Robak, T. (1997) 2-Chloro-deoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukemia. European Journal of Cancer, 33, 170-173.